128 related articles for article (PubMed ID: 19405786)
1. Genotype-based therapeutic approach for colorectal cancer: state of the art and future perspectives.
Fogli S; Caraglia M
Expert Opin Pharmacother; 2009 May; 10(7):1095-108. PubMed ID: 19405786
[TBL] [Abstract][Full Text] [Related]
2. Implications of genetic testing in the management of colorectal cancer.
Stoehlmacher J; Lenz HJ
Am J Pharmacogenomics; 2003; 3(2):73-88. PubMed ID: 12749725
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics in colorectal carcinomas: future perspectives in personalized therapy.
Russo A; Corsale S; Cammareri P; Agnese V; Cascio S; Di Fede G; Macaluso M; Bazan V
J Cell Physiol; 2005 Sep; 204(3):742-9. PubMed ID: 15828025
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms in the thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity to capecitabine-raltitrexed in colorectal cancer.
Salgado J; Zabalegui N; Gil C; Monreal I; Rodríguez J; García-Foncillas J
Oncol Rep; 2007 Feb; 17(2):325-8. PubMed ID: 17203168
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics in cancer chemotherapy: balancing toxicity and response.
Donnelly JG
Ther Drug Monit; 2004 Apr; 26(2):231-5. PubMed ID: 15228171
[TBL] [Abstract][Full Text] [Related]
6. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Zhu AX; Puchalski TA; Stanton VP; Ryan DP; Clark JW; Nesbitt S; Charlat O; Kelly P; Kreconus E; Chabner BA; Supko JG
Clin Colorectal Cancer; 2004 Feb; 3(4):225-34. PubMed ID: 15025795
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetic tailoring of irinotecan-based first-line chemotherapy in metastatic colorectal cancer: results of a pilot study.
Freyer G; Duret A; Milano G; Chatelut E; Rebischung C; Delord JP; Merrouche Y; Lledo G; Etienne MC; Falandry C
Anticancer Res; 2011 Jan; 31(1):359-66. PubMed ID: 21273624
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.
Cortejoso L; López-Fernández LA
Pharmacogenomics; 2012 Jul; 13(10):1173-91. PubMed ID: 22909207
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacogenetics and tumor sensitivity of antineoplastic agents. Application to colorectal cancer].
Milano G
Rev Prat; 2008 May; 58(10):1056-9. PubMed ID: 18652401
[TBL] [Abstract][Full Text] [Related]
10. Rational selection of predictive pharmacogenomics test for the Fluoropyrimidine/Oxaliplatin based therapy.
Di Francia R; De Lucia L; Di Paolo M; Di Martino S; Del Pup L; De Monaco A; Lleshi A; Berretta M
Eur Rev Med Pharmacol Sci; 2015 Nov; 19(22):4443-54. PubMed ID: 26636535
[TBL] [Abstract][Full Text] [Related]
11. [State of the art of pharmacogenetic diagnostics in drug therapy].
Kirchheiner J; Seeringer A; Brockmöller J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776
[TBL] [Abstract][Full Text] [Related]
12. DMET™ (Drug-Metabolizing Enzymes and Transporters) microarray analysis of colorectal cancer patients with severe 5-fluorouracil-induced toxicity.
Rumiato E; Boldrin E; Amadori A; Saggioro D
Cancer Chemother Pharmacol; 2013 Aug; 72(2):483-8. PubMed ID: 23760813
[TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics and irinotecan therapy.
Hahn KK; Wolff JJ; Kolesar JM
Am J Health Syst Pharm; 2006 Nov; 63(22):2211-7. PubMed ID: 17090741
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenetics of fluoropyrimidine and cisplatin. A future application to gastric cancer treatment.
Shimoyama S
J Gastroenterol Hepatol; 2009 Jun; 24(6):970-81. PubMed ID: 19638079
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics in chemotherapy of colorectal cancer.
Henriette Tanja L; Guchelaar HJ; Gelderblom H
Best Pract Res Clin Gastroenterol; 2009; 23(2):257-73. PubMed ID: 19414151
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM; Meijerman I; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
[TBL] [Abstract][Full Text] [Related]
17. Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients.
van Huis-Tanja LH; Ewing E; van der Straaten RJ; Swen JJ; Baak-Pablo RF; Punt CJ; Gelderblom AJ; Guchelaar HJ
Pharmacogenet Genomics; 2015 Jun; 25(6):279-88. PubMed ID: 25815774
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
Perera MA; Innocenti F; Ratain MJ
Pharmacotherapy; 2008 Jun; 28(6):755-68. PubMed ID: 18503403
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenetic aspects in treatment of colorectal cancer--an update.
Stoehlmacher J; Goekkurt E; Lenz HJ
Pharmacogenomics; 2003 Nov; 4(6):767-77. PubMed ID: 14596640
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics in colorectal cancer: a systematic review.
Funke S; Brenner H; Chang-Claude J
Pharmacogenomics; 2008 Aug; 9(8):1079-99. PubMed ID: 18681783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
